Efficacy and safety of nintedanib in patients with idiopathic pulmonary fibrosis who are elderly or have comorbidities

BACKGROUND: Idiopathic pulmonary fibrosis (IPF) predominantly affects individuals aged > 60 years who have several comorbidities. Nintedanib is an approved treatment for IPF, which reduces the rate of decline in forced vital capacity (FVC). We assessed the efficacy and safety of nintedanib in pat...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Respir Res
Autors principals: Glaspole, Ian, Bonella, Francesco, Bargagli, Elena, Glassberg, Marilyn K., Caro, Fabian, Stansen, Wibke, Quaresma, Manuel, Orsatti, Leticia, Bendstrup, Elisabeth
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2021
Matèries:
Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8073950/
https://ncbi.nlm.nih.gov/pubmed/33902584
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12931-021-01695-y
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars